Proteomic Studies of Age-Related Ocular Diseases

ByConnor Hodde

A Cleveland Clinic lab has found evidence to support the theory that age-related macular degeneration (AMD) is an inflammatory disease with varying ways to progress to advanced dry and wet AMD.  Focusing on proteomic studies to discover biomarkers and molecular mechanisms of AMD and glaucoma, John W. Crabb, PhD, and his colleagues found many proteins associated with the immune response and cellular defense.  The research goals are to develop methods that help clinicians identify who is susceptible to progression in age-related ocular disease, and that helps them assess the effectiveness of therapeutics.

Read the entire article here.

Similar Posts

Scientists Develop Nanoscale Capsules Capable of Producing Medicines in Human Body

ByConnor Hodde

In a boost to localized disease treatment, research has yielded micro and nano-scale protein making machinery in capsule form, capable of manufacturing drugs inside the human body. The study was published in American Chemical Society’s (ACS) journal, Nano Letters. Proteins are the building blocks of drugs and integral to the human cell. Read more at…

Retinitis Pigmentosa: FDA approves first retinal implant for advanced adult RP

ByConnor Hodde

Retinitis pigmentosa (RP) is a group of inherited disorders characterized by progressive peripheral vision loss and night vision difficulties (nyctalopia) that can lead to central vision loss. The US Food and Drug Administration (FDA) has approved the first retinal implant, the Argus II Retinal Prosthesis System, for adults aged 25 years or older with advanced RP. The…

Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

ByConnor Hodde

Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…

Isis Pharmaceuticals’ License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

ByConnor Hodde

Isis Pharmaceuticals, Inc. (ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.  After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.  ISIS-FXIRx is an…

Mayo Clinic work shows possible Lucentis side effect

ByConnor Hodde

At the Amercian Academy of Opthalmology 115th Annual Meeting, findings were presented from a retrospective study conducted after a Mayo Clinic opthalmologist noticed an increase in intraoccular pressure (IOP) in her patients using Genentech’ (Roche) Lucentis (ranibizumab), an FDA-approved drug for the treatment of age-related macular degeneration (AMD). MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial…